reports
Resolutions from Zealand Pharma's Annual General Meeting 2025
Resolutions from Zealand Pharma's Annual General Meeting 2025 Company announcement – No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today held its Annual General Meeting of 2025 as a partly electronic and partly physical general meeting (hybrid meeting). At the Annual General Meeting, all proposals presented to the Annual General Meeting were approved. P...
Zealand Pharma major shareholder announcement: Van Herk Investments B....
Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, March 25, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 24 March 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 24 March 2025, Van Herk Investments B.V. (Dutch ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
- Jacob Mekhael
Zealand Pharma Model update reflects added value of Roche deal
Following Zealand's recent partnership announcement to co-develop and co-commercialise petrelintide with Roche, we dive deeper into the details of the deal and provide an up to date view on the status of Zealand's key programs in obesity. Additionally, we update our model to incorporate the cash injection and milestones, while also increasing our R&D, SG&A and peak sales estimates for petrelintide. All in all, we land at a higher TP of DKK 1120 (from DKK 970), and reiterate our Buy rating. For t...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 27,425 divided into 27,425 new shares with a nominal value of DKK 1 ea...
- Jacob Mekhael
Zealand Pharma Completes petrelintide phase 2b enrolment in obesity/ov...
Zealand announced that the last participant has been enrolled and randomised in the phase 2b (ZUPREME-1) trial of petrelintide (long acting amylin analog, SC) in people with obesity or overweight with weight-related comorbidities. While the company has not provided specific guidance for when results will be released, we expect this to be around 1Q26 taking into account the 42 week treatment period. We reiterate our DKK 970 TP and BUY rating.
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Lewi
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPR...
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment.Zealand Pharma remains on track to initiate the Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabet...
- Jacob Mekhael
Zealand Pharma FIRST LOOK: Roche petrelintide partnership conference c...
Zealand hosted a conference call to discuss the co-development and co-commercialisation partnership with Roche for petrelintide announced this morning. Our key learning was that the 50/50 profit share remains in place even if Zealand decides to be less than 50% involved in the commercial roll out, which further points to the attractiveness of the terms the company has been able to secure. We summarise the key takeaways from the conference call.
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Jacob Mekhael
Zealand Pharma Ambitious agreement with Roche sets petrelintide up to ...
Zealand has secured an ambitious global collaboration and license agreement with Roche to co-develop and co-commercialise petrelintide (amylin analog) as a foundational therapy for weight management with 50/50 commercialisation rights in the US and Europe and $1.65b upfront. This deal validates the potential of amylin as the next hot target in obesity management, and with Roche onboard, we believe petrelintide is on the right path to capture a good chunk of this growing market (we est. petrelint...
Zealand Pharma and Roche enter collaboration and license agreement to ...
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity The companies will co-develop and co-commercialize petrelintide monotherapy and potential combination products, including petrelintide/CT-388, in the U.S. and EuropeZealand Pharma will ...
Zealand Pharma convenes its Annual General Meeting 2025
Zealand Pharma convenes its Annual General Meeting 2025 Company Announcement – No. 3 / 2025 Zealand Pharma convenes its Annual General Meeting 2025 Notice to convene the Annual General Meeting 2025 of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Thursday, March 27, 2025 at 3:00 pm (CET) The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting). The Annual General M...
Correction: Zealand Pharma Announces Financial Results for the Full Ye...
Correction: Zealand Pharma Announces Financial Results for the Full Year 2024 Company announcement – No. 2 / 2025 Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to come Positive results with long-acting amylin analog petrelintide in 16-week Phase 1b trial and advancement into large, comprehensive Phase 2b trial in people with overweight or...
- Thomas Vranken
Zealand Pharma FIRST LOOK: FY24 results underline pipeline progress
Zealand reported its FY24 results, highlighting significant progress in its pipeline. Key developments include positive results for petrelintide, dapiglutide, and survodutide, with several trials advancing to the next phases in 2025. The company reported a YE24 cash position of $ 1.3bn, supporting accelerated momentum in 2025 with important clinical advancements while it aims to secure a partnership for petrelintide. We reiterate our DKK 970 TPP and Buy rating.
- Guy Sips
- Hilde Van Boxstael
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
Zealand Pharma Announces Financial Results for the Full Year 2024
Zealand Pharma Announces Financial Results for the Full Year 2024 Company announcement – No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to come Positive results with long-acting amylin analog petrelintide in 16-week Phase 1b trial and advancement into large, comprehensive Phase 2b trial in people with overweight or obesity Positive topline results with GLP-1/GLP-2 receptor dual agonist dapi...
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to p...
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results Press Release – No. 3 / 2025 Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results Copenhagen, Denmark, February 13, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it will host a conference call on February 20, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial...
- Jacob Mekhael
Zealand Pharma FIRST LOOK: Amycretin data supportive of amylin's weigh...
In Zealand related news, Novo Nordisk (no coverage) reported phase 1b/2a results for amycretin (GLP-1/amylin receptor agonist) in 125 people with overweight/obesity on Friday during trading hours, which led Novo to trade +13% intraday and Zealand +7% intraday. The results demonstrated 22% weight loss (24% placebo adjusted) at 36 weeks on the 20mg dose. While no information has been published on the receptor biology of amycretin, making direct comparisons with Zealand's petrelintide difficult, we...
- Hilde Van Boxstael
- Jacob Mekhael
- Sharad Kumar S.P
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.